Over the past 12 months, 19 insiders at IONIS PHARMACEUTICALS INC filed 163 open-market SEC Form 4 transactions on IONS: 0 purchases worth $0 and 163 sales worth $167.5M. Insiders have been net sellers over this period. The most recent filing was on Jul 7, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 7, 26 | C Frank BennettEVP, Chief Scientific Officer | SELL | 15.0K | $85.46 | $1.3M |
| Jul 7, 26 | Allene M. Diaz | SELL | 10.1K | $85.42 | $864K |
| Jul 7, 26 | Holly B. KordasiewiczEVP, Chief Development Officer | SELL | 362 | $84.30 | $31K |
| Jul 1, 26 | Joseph Klein III | SELL | 11.4K | $79.45 | $903K |
| Jun 26, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 5.6K | $80.16 | $452K |
| Jun 15, 26 | Spencer R Berthelsen | SELL | 8.0K | $73.49 | $588K |
| Jun 1, 26 | Spencer R Berthelsen | SELL | 8.0K | $75.67 | $605K |
| Apr 28, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 1.6K | $71.79 | $117K |
| Apr 16, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 5.6K | $74.56 | $419K |
| Apr 16, 26 | Brian BirchlerEVP, Corp and Development Ops | SELL | 973 | $75.04 | $73K |
| Mar 19, 26 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | SELL | 5.8K | $70.97 | $412K |
| Mar 17, 26 | Elizabeth L HougenEVP, Finance & CFO | SELL | 10.2K | $73.21 | $745K |
| Mar 16, 26 | Elizabeth L HougenEVP, Finance & CFO | SELL | 205.6K | $72.77 | $14.9M |
| Mar 10, 26 | Kyle JenneEVP, Chf GL Pdt Str Ofcr | SELL | 21.2K | $76.30 | $1.6M |
| Mar 10, 26 | Brett P MoniaChief Executive Officer | SELL | 17.6K | $76.34 | $1.3M |
| Mar 9, 26 | Brett P MoniaChief Executive Officer | SELL | 117.6K | $75.58 | $8.9M |
| Mar 9, 26 | Patrick R. O'NeilEVP CLO & General Counsel | SELL | 10.1K | $75.25 | $764K |
| Mar 4, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 238 | $80.00 | $19K |
| Mar 4, 26 | Joseph LoscalzoDirector | SELL | 200 | $80.00 | $16K |
| Mar 3, 26 | C Frank BennettEVP, Chief Scientific Officer | SELL | 71.6K | $80.76 | $5.7M |
| Mar 3, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 4.1K | $81.01 | $325K |
| Mar 3, 26 | Shannon L. DeversEVP, Chief Human Resources Ofc | SELL | 14.3K | $80.84 | $1.1M |
| Mar 3, 26 | Allene M. DiazDirector | SELL | 39.3K | $80.80 | $3.1M |
| Mar 3, 26 | Joseph Klein IIIDirector | SELL | 13.5K | $80.82 | $1.1M |
| Mar 3, 26 | Joseph LoscalzoDirector | SELL | 832 | $80.33 | $67K |
| Feb 13, 26 | Eric SwayzeEVP Research | SELL | 9.4K | $82.07 | $770K |
| Feb 11, 26 | B Lynne ParshallDirector | SELL | 5.0K | $82.72 | $414K |
| Feb 6, 26 | Brett P MoniaChief Executive Officer | SELL | 29.4K | $85.79 | $2.5M |
| Feb 2, 26 | C Frank BennettEVP, Chief Scientific Officer | SELL | 48.6K | $83.03 | $4.0M |
| Jan 30, 26 | C Frank BennettEVP, Chief Scientific Officer | SELL | 5.9K | $82.95 | $488K |
| Jan 30, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 5.3K | $82.96 | $439K |
| Jan 30, 26 | Brian BirchlerEVP, Corp and Development Ops | SELL | 6.2K | $83.03 | $513K |
| Jan 30, 26 | Elizabeth L HougenEVP, Finance & CFO | SELL | 7.0K | $83.24 | $582K |
| Jan 30, 26 | Brett P MoniaChief Executive Officer | SELL | 63.0K | $82.72 | $5.2M |
| Jan 30, 26 | Patrick R. O'NeilEVP CLO & General Counsel | SELL | 6.2K | $83.53 | $516K |
| Jan 30, 26 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | SELL | 6.2K | $83.45 | $516K |
| Jan 30, 26 | Eric SwayzeEVP Research | SELL | 6.2K | $82.93 | $512K |
| Jan 22, 26 | Shannon L. DeversEVP, Chief Human Resources Ofc | SELL | 4.0K | $81.34 | $323K |
| Jan 16, 26 | C Frank BennettEVP, Chief Scientific Officer | SELL | 9.0K | $75.15 | $675K |
| Jan 16, 26 | Joseph BaroldiEVP, Chief Business Officer | SELL | 6.9K | $75.78 | $523K |
| Jan 16, 26 | Brian BirchlerEVP, Corp and Development Ops | SELL | 8.5K | $75.11 | $637K |
| Jan 16, 26 | Shannon L. DeversEVP, Chief Human Resources Ofc | SELL | 8.4K | $75.95 | $634K |
| Jan 16, 26 | Elizabeth L HougenEVP, Finance & CFO | SELL | 12.9K | $75.22 | $972K |
| Jan 16, 26 | Kyle JenneEVP, Chf GL Pdt Str Ofcr | SELL | 1.8K | $75.96 | $138K |
| Jan 16, 26 | Holly B. KordasiewiczEVP, Chief Development Officer | SELL | 4.1K | $75.66 | $313K |
| Jan 16, 26 | Brett P MoniaChief Executive Officer | SELL | 44.0K | $74.82 | $3.3M |
| Jan 16, 26 | Patrick R. O'NeilEVP CLO & General Counsel | SELL | 9.2K | $75.84 | $697K |
| Jan 16, 26 | Eugene SchneiderEVP, Chf Clinical Develop Ofcr | SELL | 9.3K | $75.59 | $703K |
| Jan 16, 26 | Eric SwayzeEVP Research | SELL | 9.9K | $75.97 | $745K |
| Jan 7, 26 | Shannon L. DeversEVP, Chief Human Resources Ofc | SELL | 25.5K | $85.36 | $2.2M |
Over the past 12 months, insiders at IONIS PHARMACEUTICALS INC filed 0 open-market purchases worth $0 and 163 sales worth $167.5M on IONS, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 7, 26.
19 different insiders at IONIS PHARMACEUTICALS INC filed open-market SEC Form 4 transactions on IONS over the last 12 months.
InsiderTape plots every IONS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every IONIS PHARMACEUTICALS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →